The Illinois Cancer Center entered 25 patients on a phase II trial of intravenous melphalan treating patients with recurrent, metastatic or locally advanced and inoperable squamous cell carcinoma of the head and neck. All patients had bi-dimensionally measurable disease, at least a sixty day life expectancy, and adequate performance status (ECOG scale ≤2). All patients except one had received prior radiotherapy, chemotherapy or both. Melphalan dosage was 30 mg/m2 every three weeks. Twenty-four patients were evaluable for response. One patient with laryngeal carcinoma had a clinical complete response of a nodal metastasis. Four patients had stabilization of disease for one to three months. There was formidable toxicity, including neutropenia (ANC < 1000/μl 36%), and thrombocytopenia (< 50,000/μl 32%). There were no drug-related deaths. Melphalan administered intravenously does not appear to be efficacious therapy in patients with previously treated advanced head and neck squamous carcinomas.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Fletcher GH: Basic principles of the combination of irradiation and surgery. Int J Radiat Oncol Biol Phys 5:2091–2096, 1979
Kies MS, Gordon LI, Hauck WW, Krespi Y, Ossoff RH, Pecaro BC, Yuska C, Lamut CH, Brand WN, Chang SK, Shetty R, Sisson GA: Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer. Otolaryngol Head Neck Surg 93(2): 199–205, 1985
Dreyfuss AI, Clark JR, Wright JE, Norris CM, Busse PM, Lucarini JW, Fallen BG, Casey D, Andersen JW, Klein R, Rosowsky A, Miller D, Frei E: Continuous infusion high dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 112:167–172, 1990
Yokes EE, Weichselbaum RR, Lippman JM, Hong WK: Head and neck cancer. N Engl J Med 328:184–194, 1993
Bosanquet AG, Gilby ED: Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18(4):355–362, 1982
Spitzer G, Jagannath S, Dicke KA, Armitage J, Zander AR, Vellekoop L, Horwitz L, Cabanillas F, Zagars GK, Velasquez WS: High dose melphalan and total body irradiation with bone marrow transplantation for refractory malignancies. Eur J Cancer Clin Oncol 22:677–684, 1986
Lokhorst HM, Meuwissen OJ, Verdonck LF, Dekker AW: High-risk multiple myeloma treated with high dose melphalan. J Clin Oncol 10:47–51, 1992
About this article
Cite this article
Kies, M.S., Grinblatt, D., Runge-Morris, M. et al. Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck. Invest New Drugs 12, 45–47 (1994). https://doi.org/10.1007/BF00873235
- Squamous Cell Carcinoma
- Squamous Carcinoma
- Measurable Disease